Why strict asthma biologic trials might be locking out the wrong patients

A strict test for a common problem

Think about being barred from testing a life belt simply because you were slightly too tall. That mirrors how many asthma drug tests select volunteers. Before a new drug reaches pharmacy shelves, experts run tests to confirm it is safe and works well. To keep tests neat, they set rigid rules. One standard hurdle is spirometry, a breath test measuring how much air you blow out in one second. This score is called FEV1.

These numbers decide who enters a trial and who leaves. In regular clinics, about two-thirds of adults with severe asthma miss these narrow benchmarks. Yet doctors still give them targeted drugs made from living cells. This raises a big question. Do strict entry rules turn away people who would not gain from care, or do they close doors needlessly?

Watching patients become their own controls

To investigate, a team looked at the CHRONICLE study. This project tracks adults with severe asthma across the United States. The team focused on 480 people who started an approved targeted drug and had asthma attacks, also called exacerbations. An exacerbation is a sudden, dangerous worsening of symptoms.

Instead of comparing treated patients to different people, the team used a method called a self-controlled case series. This design lets each patient serve as their own comparison. The team counted severe attacks in the twelve months before starting the drug. Then they counted attacks in the twelve months after. Because each person is compared only to themselves, fixed traits like genetics and sex naturally balance out. Across the group, starting the drug cut severe attacks by 57%. This drop neatly matched results from earlier trials.

The numbers that did not matter

The team then checked if standard trial rules altered that 57% drop. They tested several breath scores, including FEV1 and the FEV1/FVC ratio. That ratio compares air blown in one second to total lung space. These hurdles would have kept out between 28.1% and 66.7% of patients. Yet none of these lung scores altered how much the drug helped.

Other chest illnesses like COPD or damaged airways also did not change the drug's success. Some signs, however, did make a difference. Patients with high breath markers like FENO—a gas indicating allergic lung swelling—had even bigger gains. A higher blood eosinophil count, measuring allergy-linked white blood cells, also meant greater gains. This study does not rule out tiny differences, and officials will likely still exclude other chest illnesses. But the findings show rigid breath rules turn away people without good reason.

What we still do not know

This study grouped six approved drugs together. It cannot tell us if individual drug types act differently when studied alone. Because only 480 patients met all checks, faint patterns might remain hidden. Finally, we do not know if drug officials will ever relax these rules in future trials.